Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX 3 CR 1 were explored in a pooled analysis of three case-control studies (San Francisco Bay Area, California; United Kingdom; total: cases N ¼ 1610, controls N ¼ 1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 D32 deletion reduced the risk of NHL (odds ratio ¼ 0.56, 95% confidence interval ¼ 0.38-0.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 D32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.
Introduction
Established risk factors for non-Hodgkin lymphoma (NHL) are related to severe immune suppression and include infection with human immunodeficiency virus-1 (HIV) and graft-versus-host disease [1] . In addition, variants in genes related to immune function, cell signaling, and steroidogenesis have been associated with NHL susceptibility and suggest etiologic differences by subtype [2] . More focused study of the association between chemokines and NHL has concentrated on AIDS-related lymphomas and was stimulated by the discovery that the chemokine receptor CCR5 is a co-receptor for HIV; carriers of the CCR5 D32 deletion are protected against HIV infection (homozygous variants) or have slower progression to AIDS (heterozygotes). Some of the initial findings showed that risk for AIDS-related lymphoma was decreased in carriers of the deletion in CCR5 D32 and increased in those with the CXCL12 (SDF-1) variant allele [3, 4] .
Chemokines first were identified about 20 years ago and initially were revealed to play a key role in leukocyte trafficking [5, 6] . Continued research has disclosed that chemokines are critical in lymphocyte development, angiogenesis, host response to infection and in inflammatory processes, especially antiviral and antitumor responses [7] [8] [9] . Additionally, T-helper 1 and 2 (Th1, Th2) cells that play a role in pro-inflammatory and anti-inflammatory immune responses can be distinguished by their chemokine production and chemokine receptor expression. For example, the receptors for chemokine ligand CCL5, CCR5, and CCR3, are differentially expressed by Th1/Th2 cells, with CCR5 predominantly expressed on Th1 cells and CCR3 predominantly expressed on Th2 cells. Chemokines expressed by B-and T-cell lymphomas have a role in tumor angiogenesis, progression, migration, and metastasis [10] [11] [12] [13] [14] . Susceptibility, development and survival of other cancers including breast, prostate, melanoma, colon and hepatocellular cancer also have been associated with chemokine expression levels and polymorphisms [15] [16] [17] [18] [19] .
To contribute new information on genetic associations between chemokines and non-AIDS-related NHL and NHL subtypes, we conducted a pooled analysis of genetic data from participants in three population-based case-control epidemiological studies of NHL in the San Francisco Bay Area, USA and in the UK. We explored associations between polymorphisms and haplotypes in chemokine genes CCR5, CCR2, CCL5 (RANTES), CXCL12 (SDF-1), and CX 3 CR 1 (fractalkine), and risk of all NHL, diffuse large B-cell, follicular and chronic lymphocytic leukemia/small lymphocytic lymphomas. Also, because data show that sex-related autoimmune diseases associated with increased NHL risk [20] may exhibit increased chemokine expression and levels [21] , and because chemokine expression differs by sex [22] [23] [24] , we explored whether chemokine gene variants associated with NHL and NHL subtypes differed by sex.
Materials and methods
Study methodologies have been published for the two large population-based case-control studies of NHL conducted in six counties in the San Francisco Bay Area (NHL1 and NHL2) [2, 25] and for the UK study [26] . Within each study, the eligibility criteria for cases and controls were identical with the exception of diagnosis with NHL. Eligible participants were those with incident NHL (all cases), able to complete an interview in English, residents of the study region at diagnosis/interview (1 of 6 San Francisco Bay Area counties for NHL1 and NHL2; 1 of 7 counties or 2 districts in the UK), alive, had no physician indicated contraindications to contact (NHL1 and NHL2 cases), or physician consent to contact (UK participants Pathology materials were reviewed to classify NHL histologic subtypes [27] using the Working Formulation (US NHL1 study) and the World Health Organization (WHO) classification (US NHL2 and UK studies). Participants provided informed consent for interview, biospecimen collection, access to pathology materials (for cases) and medical records (UK study). Study protocols were approved by the review committee for human research at the University of California, San Francisco and by the United Kingdom Multi-Regional Ethical Committee.
Genotyping DNA was isolated from purified blood mononuclear cells using a Qiagen column method. For the NHL1 and UK studies, *40 ng of DNA was used for the initial polymerase chain reaction. PCR products were purified to remove unincorporated dNTP's and to digest unused primers. Genotypes were determined using three different single-base extension (SBE) reactions (Applied Biosystems, Foster City, CA) on an ABI Prism SNaPshot Multiplex Kit. Each SBE reaction contained 5 mL SNaPshot Multiplex Ready Reaction Mix and 1.5 pmol of each SBE primer. Reaction A (10 mL) consisted of 3 mL of purified PCR product and 1.5 pmol of SBE primer (CX 3 CR 1 249, CX 3 CR 1 280, CCR2 64I, CCR5 D32). Reaction B (10 mL) combined 4 mL purified PCR product with 1.5 pmol of SBE primer (CCR5 59029, CCR5 59353, CCL5 -403, CXCL12 3 0 A). Reaction C (10 mL) contained 3 mL of purified PCR product (CCR5 59653) and 1. For the NHL2 study genotyping for interim analyses [2] was performed using the Illumina GoldenGate assay on a BeadStation 500G Genotyping System (2 SNPs in CX 3 CR 1 and 1 SNP in CCL5) as previously described [2] . Genotype calls were made using the GenCall version 6.2.0.4 software package (Illumina, San Diego, CA) [2] . Genotype data were accessed for 2 SNPS in CX 3 CR 1 that were genotyped as part of a genome-wide association study (GWAS) of NHL. In this GWAS, DNA from 757 cases with NHL and 811 control participants was genotyped using the Illumina Human CNV370-Duo BeadChip (Illumina, San Diego, CA), that includes 4370 000 markers, providing 81% of the HapMap variation at r 2 4 0.8 in a Caucasian (HapMap-CEU) population. Genotype clustering was conducted with the Illumina Beadstudio software from data files created by the Illumina BeadArray reader. Samples and markers with call rates below 95% were excluded from further analysis.
Statistical analysis
Genotype analyses were restricted to HIV-negative non-Hispanic Caucasians (NHL1: cases N ¼ 262, controls N ¼ 516; NHL2: cases N ¼ 1124, controls N ¼ 1235; UK: cases N ¼ 224, controls N ¼ 241) All nine polymorphisms of interest were genotyped in the NHL1 study, three in the NHL2 study and four in the UK study (Table I) . For each polymorphism, Hardy-Weinberg equilibrium (HWE) was tested among controls. Unconditional logistic regression adjusted for frequency-matched variables and study was used to estimate the risk of NHL, DLCL, FL and CLL/SLL associated with genotype. Participants with the most common genotype or haplotype based on the frequency among controls were the referent group. Genotypes categorized as homozygous wild type (wt/wt), heterozygous (wt/var), and homozygous variant (var/var) were treated as ordinal variables in tests for linear trend. Haplotypes were explored in CX 3 CR 1 and in CCR2 and CCR5 based on results from earlier studies suggesting that haplotypes in these genes were associated with HIV progression [28, 29] . Haplotype blocks and measures of linkage disequilibrium (D 0 and r 2 ) were estimated using Haploview [30] and the four-gamete rule assuming a 1% probability for observing the fourth gamete. Haplotype analyses were conducted for all NHL and by common NHL subtypes DLCL, FL and CLL/SLL using haplo.stats in R v2.8.1 (www.r-project.org) that uses an estimationmaximization (EM) algorithm to infer unphased haplotype probabilities. Haplotype effects were estimated using a weighted adjusted logistic regression in a two-step EM algorithm [31] . SNPassoc in R was used to conduct analyses of haplotype-sex interactions and to obtain risk estimates from stratified models. Haplotypes with a frequency of 55% were Table I . Chemokine and chemokine receptor polymorphisms genotyped in three pooled population-based case-control studies, San Francisco Bay Area, US (NHL1, NHL2) and UK.
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Results
In the pooled population, the median age of patients at diagnosis was 60 years (NHL1 ¼ 60 years, NHL2 ¼ 62 years, UK ¼ 55 years) and the median age of controls at interview was 59 years (NHL1 ¼ 52 years, NHL2 ¼ 64 years, UK ¼ 55 years). There were a greater proportion of men (927 cases, 1190 controls) than women (683 cases, 802 controls) with the predominance of men also observed by study (NHL1 ¼ 66%, NHL2 ¼ 58%, UK ¼ 52%) and within the NHL subtype subgroups.
Genotype frequencies among controls were in HWE (all p 4 0.24). There was no evidence of heterogeneity in genotype odds ratios across studies (Breslow-Day test, all p 4 0.12). Age-, sex-, and study-adjusted analyses showed no association between chemokine gene polymorphisms and risk of all NHL (Table II) . Results from analyses by DLCL, FL and CLL/SLL subtypes were consistent with results for all NHL with one exception: decreased risk of FL and of CLL/SLL was observed among carriers of the CCL5 -403 (RANTES) variant allele (OR ¼ 0.78, p trend ¼ 0.02; OR ¼ 0.64, p trend ¼ 0.004; respectively). No other chemokine polymorphism was associated with risk of these common NHL subtypes.
Analyses to assess gene-sex interaction showed that the association between risk of NHL and the CCR5 D32 (rs333) polymorphism was modified by sex (p interaction ¼ 0.01, Table III ). Decreased risk of NHL was observed in men (OR ¼ 0.56) but not in women (OR ¼ 1.2) who carried the CCR5 D32 deletion (Table III) . Similar CCR5 D32-sex interaction effects were observed for DLCL and FL (p interaction ¼ 0.05, p interaction ¼ 0.10, respectively; Table III ). Men with the deletion were less likely to have been diagnosed with DLCL (OR ¼ 0.55, p ¼ 0.03) or FL (OR ¼ 0.59, p ¼ 0.06) compared with men without the deletion. Statistical interaction with sex also was evident for other CCR5 polymorphisms, 59029 (rs1799987), and 59353 (rs1799988). However, these polymorphisms were analyzed in the NHL1 study only and no individual ORs for the associated genotypes differed from unity. Similarly, no individual OR differed from unity for the suggested CX 3 CR 1 249-sex interaction observed in FL (Table III) .
Analyses for CCR2/CCR5 (all D 0 40.96) and for CX 3 CR 1 (D 0 ¼ 1.0) haplotypes were conducted for all NHL and by DLCL and FL subtypes (Table IV) . The CCR2/CCR5 referent haplotype comprised the common alleles for the CCR2 and CCR5 polymorphisms. In these analyses, there was an indication of haplotype-sex interaction (p interaction ¼ 0.045, Table IV ). Haplotype B, the only haplotype with the CCR5 D32 deletion, was associated with reduced NHL risk among men (OR ¼ 0.57, p ¼ 0.02) but was increased somewhat among women (OR ¼ 1.6, p ¼ 0.10) compared with the referent (Table IV) Table IV ).
Discussion
Our results showed that HIV-negative nonHispanic Caucasian men who carry the CCR5 D32 deletion were less likely to have been diagnosed with all NHL, DLCL, or FL compared with men without the deletion. Further, the CCR2/CCR5 haplotype characterized by the CCR5 D32 deletion was the only CCR2/CCR5 haplotype associated with reduced risk of NHL among men. In addition, the CCL5-403 (RANTES) variant allele was associated with a reduced risk of FL and of CLL/SLL with no evidence of a sex-specific effect. No associations were observed for other chemokine polymorphisms or among women only. Although patterns of association showed some consistency, a number of statistical tests were conducted and sparse data in some sexstratified analyses resulted in low power to test hypotheses. Therefore, results from these analyses should be interpreted conservatively and require further confirmation in other large studies.
Chemokines play an important role in B-cell development and maturation [32] , and their expression on B-and T-cells varies between normal and neoplastic cells and by type of lymphoproliferative disorder [10, 11, 14] . Several variants in chemokine genes have been associated with increased risk of AIDS-related NHL although we found no published reports that evaluated chemokine gene polymorphisms and susceptibility to NHL, DLCL, FL, or CLL/SLL in a population-based study among Table II HIV-negative participants. Investigated in susceptibility studies of other cancers, genetic variability in CCR2, CCR5, and CXCL12 has been associated with hepatocellular carcinoma [15] , cervical [33] , pancreatic [34] , and prostate cancers [16] , whereas increased expression of chemokines including CXCL12 (SDF-1) and CCL5 (RANTES) has contributed to tumor angiogenesis, metastasis, progression and survival in breast, prostate and colon cancers (reviewed in [35, 36] ).
The decreased NHL risk with the CCR5 D32 deletion and no association with the CCR2-64I variant allele among men in our pooled population is consistent with results for AIDS-related B-cell NHL [4] . Our finding of a CCR5 D32 deletion effect on risk of DLCL or FL in HIV-negative nonHispanic Caucasian men has not been reported previously. Furthermore, only the CCR2/CCR5 haplotype that included the CCR5 D32 deletion was associated with decreased NHL risk in men and not Table III . Pooled OR and 95% CI for risk of all NHL, DLCL and FL lymphoma associated with polymorphisms in chemokine and chemokine receptor genes by sex in HIV-negative non-Hispanic Caucasians, UK and San Francisco Bay Area.
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Chemokine polymorphism Genotype [38] . The reduced risk of FL and CLL/SLL associated with the -403 G 4 A variant located in the promoter region of CCL5 has not been reported previously. However, in recent studies of other cancers, the CCL5 -403A allele was associated with a decreased risk for gastric cancer in women [17] , an increased risk for prostate cancer in men [39] and an increased risk of pancreatic cancer especially among those with a history of pancreatitis [34] . The -403 A allele results in up-regulation of CCL5, and also has been associated with increased risk of atopy [40] [41] [42] . These data suggest that CCL5 up-regulation may increase the Th2 response, possibly through increased binding sites for CCR3. Thus, NHL susceptibility may be altered through a pathway/ mechanism that is similar to that for atopy. In contrast, studies of other cancers have assessed CCL5 expression [43] [44] [45] [46] and have found that increased expression was related to cancer progression, cell survival, and metastasis. Further, CCL5 increases transcription of angiogenic factors, especially matrix metalloprotease-9, [47] which in turn releases VEGF from endothelial cell membranes, thus contributing to tumor angiogenesis. The apparent disparate genetic effects on susceptibility, tumor progression, and metastasis may be partly explained by the differential effects of the CCL5 -403A polymorphism in other cancers, the redundancy in chemokines such that most chemokines bind to multiple receptors that are expressed on a variety of cell types and tissues, and the reported pleiotropic effects of CCL5 [48] . Additional research is needed to clarify the role of CCL5 in biologic pathways and mechanisms that may influence cancer development and progression.
Differential sex-effects of NHL risk associated with CCR5 polymorphisms have not been published for other NHL studies. The overall frequency of the CCR5 D32 deletion in our pooled control population was consistent with that observed in other populations of European Caucasians [49] although no comparable data have been published for sex-specific CCR5 D32 genotype frequencies. Some supportive evidence for potential gene-sex effects of CCR5 SNPs with disease susceptibility has been provided by a study of gastric cancer [17] and studies of other chronic diseases, diabetes [50] , and Lofgren syndrome [51] . In vitro data showing that estrogens alter chemokine expression also may partly explain our sex-specific results. However, the most compelling data have come from a study among transsexuals where in vivo, estrogens plus anti-androgens in maleto-female transsexuals increased the expression of several chemokine receptors including Th1-predominant CCR5 whereas testosterone in female-tomale transsexuals resulted in a switch to a Th2 pathway as exhibited by a diminished Th1/Th2 cytokine expression ratio [22] . In contrast, sexrelated chemokine effects from the few studies of other chronic diseases have not shown a consistent sex-pattern of risk [17, 50, 51] . Also, despite restricting our analyses to non-Hispanic white participants, it is possible that underlying population stratification may have influenced our results, even in a relatively homogeneous population. Therefore, although intriguing, our results should be interpreted cautiously and warrant continued research to confirm and clarify potential sex-related effects on immune function.
Our pooled results provide new data on risk of NHL and NHL subtypes to suggest that functional genetic polymorphisms in the chemokine CCL5 and its receptor CCR5 alter NHL susceptibility mainly in men. There was some suggestion that the polymorphism effects may differ by NHL subtype with inverse associations for CCL5 observed mainly in FL and CLL/SLL, whereas inverse associations with CCR5 were observed for DLCL and FL. Given the key role of chemokines in cell trafficking, in inflammatory processes and in the development and prognosis of AIDS-related NHL and other cancers, it is plausible that polymorphisms in these chemokines influence susceptibility for non-AIDSrelated lymphoma. However, our results should be interpreted conservatively as a number of statistical tests were conducted and there were a small number of exposed in some analyses. Larger pooled studies with increased power to test potential effects by sex and by NHL subtype are needed to confirm our findings.
